If you first look at filgotinib, Gilead and us, initiated Phase 2 trials in 8 new indications on top of the 3 that were already ongoing. We also showed very nice DARWIN 3 results which is the long-term expansion study from the DARWIN 1 and DARWIN 2 trials that confirmed the profile with respect to activity and safety profile in rheumatoid arthritis. As we initiated the building of the commercial organization that Galapagos – that will prepare Galapagos for the launch of filgotinib in 8 European countries, so a good start in that side and that activity and that will accelerate in 2018 clearly.
In IPF, idiopathic pulmonary fibrosis, we saw very nice data in a 12-week study, where we halted the disease progression in these patients, which gave us a lot of confidence that we have some very interesting molecule that will move into late stage trials in 2018. And on top of that, we announced that we have two other mechanism of actions that will move forward in IPF, so that enables us to build a franchise here of three independent molecules moving forward that on its own or in combination maybe good treatment for this deadly disease. In cystic fibrosis, we saw good results with our corrector 1 in-patient study in the ALBATROSS and FLAMINGO studies and we are now preparing to launch our first triple combination study that is our potentiator corrector 1 and corrector 2 in triple patients called FALCON, which is on track to start this quarter and we are looking forward to that dataset later in the year. But clearly, Galapagos is more than these three indications, we see in continuously expanding pipeline, very nice data in our collaboration with MorphoSys, MOR106, our IL-17C antibody, where we showed promising data in atopic dermatitis patients and we showed very strong data with regard to a biomarker in osteoarthritis patients with our molecule 1972. These are just some of the clinical highlights, we also had a lot of them new developments in our preclinical pipeline that hopefully will get to the clinic shortly.
If we can go to the next slide you see our track to get to the market with our molecule and with our organization where last year showed us our second and third proof of concept with novel target in patients. This year and next year we will continue to show data in the pivotal trials for filgotinib and also expansion of the latest stage pipeline. And that would lead in 2020, 2022 to the introduction of multiple products on the market starting with filgotinib that followed with other products from our pipeline. And hopefully we will see a number of programs the early stage programs moving forward to late stage development. So a lot is ongoing and it can be expected.
If we step back and look at filgotinib on the next slide, you will see that that is in a massive franchise now, where we started with rheumatoid arthritis that is expanded in Phase 3 trials in Crohn’s and UC and then all wings of Phase 2 trials that were initiated by Galapagos and by Gilead. And so filgotinib is being tested in this whole range of autoimmune inflammatory diseases and hopefully will lead to a number of indications where this can reach the market. To give you more detail on that, I would love to hand it over to Walid to discuss